Nicolas Guibert

Nicolas Guibert

Auto-generated profile, based on publicly available information

Nicolas Guibert

Occupational Health and Medicine Department, Hospices Civils de Lyon, Université Claude Bernard Lyon1, Ifsttar, UMRESTTE, UMR T_9405, Lyon University, Avenue Rockefeller, Lyon 69008, France

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2021 in Nature
Verified
Journal Article
Closed access
PDF file
BPBruno Pozzetto
Bruno Pozzetto
VLVincent Legros
Vincent Legros
SDSophia Djebali
Sophia Djebali
VBVéronique Barateau
Véronique Barateau
NGNicolas Guibert
Nicolas Guibert
STSophie Trouillet-Assant
Sophie Trouillet-Assant

15 March 2023 in Science Translational Medicine
Verified
Journal Article
Closed access
VBVéronique Barateau
Véronique Barateau
LPLoïc Peyrot
Loïc Peyrot
CSCarla Saade
Carla Saade
BPBruno Pozzetto
Bruno Pozzetto
KBKaren Brengel-Pesce
Karen Brengel-Pesce
TDThierry Defrance
Thierry Defrance
The diversity of vaccination modalities and infection history are both variables that have an impact on the immune memory of individuals vaccinated against SARS-CoV-2. To gain more accurate knowledge of how these parameters imprint on immune memory, we conducted a long-term follow-up of SARS-CoV-2 spike protein–specific immune memory in unvaccinated and vaccinated COVID-19 convalescent individuals as well as in infection-naïve vaccinated individuals. Here, we report that individuals from the convalescent vaccinated (hybrid immunity) group have the highest concentrations of spike protein–specific antibodies at 6 months after vaccination. As compared with infection-naïve vaccinated individuals, they also display increased frequencies of an atypical mucosa-targeted memory B cell subset. These individuals also exhibited enhanced T H 1 polarization of their SARS-CoV-2 spike protein–specific follicular T helper cell pool. Together, our data suggest that prior SARS-CoV-2 infection increases the titers of SARS-CoV-2 spike protein–specific antibody responses elicited by subsequent vaccination and induces modifications in the composition of the spike protein–specific memory B cell pool that are compatible with enhanced functional protection at mucosal sites.

1 January 2008 in CIRP Annals
Verified
Journal Article
Closed access
HPH. Paris
H. Paris
DBDaniel Brissaud
Daniel Brissaud
AGAlexander GOUSKOV
Alexander GOUSKOV
NGN. Guibert
N. Guibert
Joël RechJoël Rech
Joël Rech

24 November 2020 in BMJ Open
Verified
Journal Article
Open access
PDF file
STSophie Trouillet-Assant
Sophie Trouillet-Assant
CVChloe Albert Vega
Chloe Albert Vega
ABAntonin BAL
Antonin BAL
JNJulie-Anne Nazare
Julie-Anne Nazare
PFPascal Fascia
Pascal Fascia
JFJean-Baptiste Fassier
Jean-Baptiste Fassier
Introduction The COVID-19 pandemic caused by SARS-CoV-2 threatens global public health, and there is an urgent public health need to assess acquired immunity to SARS-CoV-2. Serological tests might provide results that can be complementary to or confirm suspected COVID-19 cases and reveal previous infection. The performance of serological assays (sensitivity and specificity) has to be evaluated before their use in the general population. The neutralisation capacity of the produced antibodies also has to be evaluated. Methods and analysis We set up a prospective, multicentric clinical study to evaluate the performance of serological kits among a population of healthcare workers presenting mild symptoms suggestive of SARS-CoV-2 infection. Four hundred symptomatic healthcare workers will be included in the COVID-SER study. The values obtained from a control cohort included during the prepandemic time will be used as reference. A workflow was set up to study serological response to SARS-CoV-2 infection and to evaluate antibody neutralisation capacity in patients with a confirmed SARS-CoV-2 infection. The sensitivity and specificity of the tests will be assessed using molecular detection of the virus as a reference. The measurement of IgM and IgG antibodies will be performed once per week for 6 consecutive weeks and then at 6, 12, 18, 24 and 36 months after the diagnosis. The kinetics of IgM and IgG will determine the optimal period to perform serological testing. The proportion of false negative PCR tests in symptomatic subjects will be determined on the basis of subsequent seroconversions. Ethics and dissemination Ethical approval has been obtained from the national review board for biomedical research in April 2020 (Comité de Protection des Personnes Sud Méditerranée I, Marseille, France) (ID RCB 2020-A00932-37). Results will be disseminated through presentations at scientific meetings and publications in peer-reviewed journals. Trial registration number NCT04341142.

21 February 2023 in medRxiv
Verified
Preprint
Open access
PDF file
NGNicolas Guibert
Nicolas Guibert
KTKylian Trepat
Kylian Trepat
BPBruno Pozzetto
Bruno Pozzetto
LJLaurence Josset
Laurence Josset
JFJean-Baptiste Fassier
Jean-Baptiste Fassier
LGLyon-COVID study group
Lyon-COVID study group
Backgroung To cope with the persistence of the Covid-19 epidemic and the decrease in antibody levels following vaccination, a third dose of vaccine has been recommended in the general population. However, several vaccine regimens had been used initially, and the heterologous ChadOx1-S/BNT162b2 regimen had shown better efficacy and immunogenicity than the homologous BNT162b2/BNT162b2 regimen. Aim We wanted to determine if this benefit was retained after the third dose. Methods We combined an observational study of SARS-COV-2 infections among vaccinated healthcare workers at the University-Hospital of Lyon, France, with an analysis of immunological parameters before and after the third mRNA vaccine dose. Results Following the second vaccine dose, heterologous vaccination regimens were more protective against infection than homologous regimens, but this was no longer the case after the third dose. RBD-specific IgG levels and serum neutralization capacity against different SARS-CoV-2 variants were higher after the third dose than after the second dose in the homologous regimen group, but not in the heterologous group. Conclusion The advantage conferred by heterologous vaccination is lost after the third dose both in terms of protection and immunogenicity. Immunological measurements suggest that heterologous vaccination induces maximal immunity after the second dose, whereas the third dose is required to reach the same level in individuals with a homologous regimen.